Su, C. (2024) “GLYCEMIC CONTROL AND BODY WEIGHT EFFECTS OF SGLT2 INHIBITORS (EMPAGLIFLOZIN 25 MG, EMPAGLIFLOZIN 12.5 MG AND DAPAGLIFLOZIN 10 MG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A SINGLE CENTRE STUDY”, Journal of the ASEAN Federation of Endocrine Societies, 39(S1), p. 25. doi: 10.15605/jafes.039.S1.037.